SWAG视频

Skip to Content Skip to Footer
Guru Betageri, PhD

Guru Betageri, PhD

Professor, Biotechnology and Pharmaceutical Sciences

College of Pharmacy

gbetageri@westernu.edu

Phone: 469-5682

Join year: 1998

  • Education

    Ph.D. University of Alberta, Edmonton, Canada 1988

    M.Pharm. Bangalore University, Bangalore, India 1982

    B.Pharm. Karnatak University, Dharwad, India 1979

    Visiting Scientist NCI, NIH Bethesda MD 1988-1989

  • Teaching Experience

    Dr. Betageri then joined the National Cancer Institute in Bethesda, Maryland as a visiting scientist, followed by a faculty appointment at Auburn University. Dr. Betageri moved to Western University in 1998, where he was promoted to Professor in 1999 and became Chairman of the Department of Pharmaceutical Sciences in 2002.

  • Research Interest

    Formulation and development of Lipid and Liposome based drug delivery systems. Enhancement of bioavailability using proliposomal system that promotes absorption through lymphatic system and eliminates first-pass effect.

    Following US patents have been issued:

    6,759,058
    6,761,901
    6,849,269
    7,387,791
    8,658,202
    8,889,180
    8,957,053
    9,445,995
    9,492,387
    8,957,053
    9,566,238
    9,623,033
    9,808,426
    9,844,557

  • Awards

    Recipient of American Association of Pharmaceutical Scientists (AAPS) Fellow Award.

  • Organizations

    Dr. Betageri is an active member of the American Association of Pharmaceutical Scientists, the American Association of Colleges of Pharmacy and the Controlled Release Society.

  • Publications

    Publications:

    1. P. Kunamaneni, S. Kovvasu, S.Yeung, J. Wang, S. Shah, G. V. Betageri.鈥淎liskiren hemifumarate proliposomes for improved oral drug delivery: formulation development, in vitro and in vivo permeability testing鈥. Molecules. 27: 4828, 2022
    2. J. Rueda, S. Kovvasu, P. Kunamaneni, G. V. Betageri. 鈥淐arvedilol solid dispersion for enhanced oral bioavailability using rat model鈥. J. Appli. Pharmaceutical Sci. 9(12): 042-050, 2019
    3. F. Onyeabor, A. Paik, S. Kovvasu, B. Ding, J. Lin, Md. A. Wahid, S. Prabhu, G. V. Betageri, J. Wang. Optimization of Preparation and Preclinical Pharmacokinetics of Celastrol-Encapsulated Silk Fibroin Nanoparticles in the Rat. Molecules. 24(18): 3271, 2019
    4. S. Kovvasu, P. Kunamaneni, R. Joshi and G.V. Betageri 鈥淪elf-emulsifying Drug Delivery Systems and their Marketed Products: A Review鈥 Asian J. Pharmaceutics 13: 73-84, 2019
    5. S. Kovvasu, P. Kunamaneni, S. Yeung, J. Rueda, G. V. Betageri. 鈥淔ormulation of Dronedarone Hydrochloride Loaded Proliposomes: In vitro and in vivo Evaluation Using Caco-2 and Rat Model鈥. AAPS PharmSciTech. 20: 226, 2019
    6. N. Swarnakar, N. Venkatesan and G. V. Betageri 鈥淐ritical in vitro Characterization Methods of Lipid-Based Formulations for Oral Delivery: a Comprehensive Review鈥 AAPS PharmSciTech 20: 2019
    7. J. Rueda, S. Kavvasu and G. V. Betageri "Daptomycin proliposomes for oral delivery: formulation, characterization, and in-vivo pharmacokinetics" has been accepted for publication in AAPS PharmSciTech. 2018
    8. V. Nekkanti, J. Rueda, Z. Wang and G.V. Betageri 鈥淐omparative evaluation of proliposomes and self micro-emulsifying drug delivery system for improved oral bioavailability of nisoldipine鈥 Int. J. Pharm. 505: 79-88, 2016
    9. V. Nekkanti, J. Rueda, Z. Wang and G.V. Betageri 鈥淒esign, Characterization, and In vivo Pharmacokinetics of Tacrolimus Proliposomes鈥 AAPS PharmSci Tech 17: 1019-1029, 2016
    10. V. Nekkanti, Z. Wang and G.V. Betageri. Pharmacokinetic Evaluation of Improved Oral Bioavailability of Valsartan: Proliposomes Versus Self-Emulsifying Drug Delivery System. AAPS PharmSciTech 17, 2016
    11. V. Nekkanti, N. Venkatesan, Z. Wang and G. V. Betageri. Improved oral bioavailability of valsartan using proliposomes: design, characterization and in vivo pharmacokinetics. Drug Dev. Ind. Pharm. 2015
    12. V. Gyanani, S. Basavaraj and G.V. Betageri. Evaluation of various processes for simultaneous complexation and granulation to incorporate Drug-Cyclodextrin complexes into solid dosage forms. Drug Dev. Ind. Pharm. 2015
    13. V. Nekkanti, N. Venkatesan and G.V. Betageri. Proliposomes for Oral Delivery: Progress and Challenges. .16:303-312, 2015
    14. S. Yanamandra, N. Venkatesan, V. Kadajji, Z. Wang, M. Issar and G.V. Betageri. Proliposomes as a drug delivery system to decrease the hepatic first-pass metabolism: Case study using a model drug. Eur. J. Pharm. Sci. 2014
    15. S. Basavaraj and G.V. Betageri. Improved oral delivery of resveratrol: Investigation of various factors contributing to prolonged absorption of un-metabolized Resveratrol. Expert Opinion on Drug Del. 2014
    16. S. Basavaraj and G.V. Betageri. Can formulation and drug delivery reduce attrition during drug discovery and development-review of feasibility, benefits and challenges. Acta Pharmaceutica Sinica B 2014

    BOOK AUTHOR:

    G. V. Betageri,S. A. Jenkins and D. L. Parsons "Liposome Drug Delivery Systems"